(Q49544319)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29282688%20AND%20SRC:MED&resulttype=core&format=json

8 April 2020

review article

1 reference

title

Cell Cycle Regulation in Treatment of Breast Cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29282688%20AND%20SRC:MED&resulttype=core&format=json

8 April 2020

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29282688%20AND%20SRC:MED&resulttype=core&format=json

8 April 2020

author name string

Zijie Cai

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29282688%20AND%20SRC:MED&resulttype=core&format=json

8 April 2020

language of work or name

English

0 references

publication date

1 January 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29282688%20AND%20SRC:MED&resulttype=core&format=json

Advances in Experimental Medicine and Biology

8 April 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29282688%20AND%20SRC:MED&resulttype=core&format=json

8 April 2020

volume

1026

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29282688%20AND%20SRC:MED&resulttype=core&format=json

8 April 2020

page(s)

251-270

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29282688%20AND%20SRC:MED&resulttype=core&format=json

Nobel Lecture. Cyclin dependent kinases and cell cycle control.

8 April 2020

cites work

1 reference

https://api.crossref.org/works/10.1007%2F978-981-10-6020-5_12

Mammalian cyclin-dependent kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-981-10-6020-5_12

Cell cycle, CDKs and cancer: a changing paradigm

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-981-10-6020-5_12

Cell-cycle checkpoints and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-981-10-6020-5_12

Cyclin-dependent kinase pathways as targets for cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-981-10-6020-5_12

FDA Approval: Palbociclib for the Treatment of Postmenopausal Patients with Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-981-10-6020-5_12

FDA Approval of Palbociclib in Combination with Fulvestrant for the Treatment of Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-981-10-6020-5_12

A systematic screen for CDK4/6 substrates links FOXM1 phosphorylation to senescence suppression in cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-981-10-6020-5_12

The Rb/E2F pathway: expanding roles and emerging paradigms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-981-10-6020-5_12

To cycle or not to cycle: a critical decision in cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-981-10-6020-5_12

Cyclin E in normal and neoplastic cell cycles

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-981-10-6020-5_12

The proliferation-quiescence decision is controlled by a bifurcation in CDK2 activity at mitotic exit

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-981-10-6020-5_12

Cyclin C/cdk3 promotes Rb-dependent G0 exit

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-981-10-6020-5_12

A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-981-10-6020-5_12

p15INK4B is a potential effector of TGF-beta-induced cell cycle arrest

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-981-10-6020-5_12

Identification of human and mouse p19, a novel CDK4 and CDK6 inhibitor with homology to p16ink4

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-981-10-6020-5_12

Novel INK4 proteins, p19 and p18, are specific inhibitors of the cyclin D-dependent kinases CDK4 and CDK6

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-981-10-6020-5_12

CDK inhibitors: positive and negative regulators of G1-phase progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-981-10-6020-5_12

Mechanisms of cyclin-dependent kinase regulation: structures of Cdks, their cyclin activators, and Cip and INK4 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-981-10-6020-5_12

Putting the stress on senescence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-981-10-6020-5_12

The meaning of p16(ink4a) expression in tumors: functional significance, clinical associations and future developments

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-981-10-6020-5_12

The molecular balancing act of p16(INK4a) in cancer and aging

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-981-10-6020-5_12

Distinct roles for cyclin-dependent kinases in cell cycle control

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-981-10-6020-5_12

Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-981-10-6020-5_12

New roles for p21 and p27 cell-cycle inhibitors: a function for each cell compartment?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-981-10-6020-5_12

New functional activities for the p21 family of CDK inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-981-10-6020-5_12

The p21(Cip1) and p27(Kip1) CDK 'inhibitors' are essential activators of cyclin D-dependent kinases in murine fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-981-10-6020-5_12

Regulation of telomere elongation by the cyclin-dependent kinase CDK1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-981-10-6020-5_12

Control of DNA synthesis and mitosis by the Skp2-p27-Cdk1/2 axis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-981-10-6020-5_12

Mitotic kinases as regulators of cell division and its checkpoints

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-981-10-6020-5_12

The anaphase-promoting complex: it's not just for mitosis any more.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-981-10-6020-5_12

Targets of the cyclin-dependent kinase Cdk1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-981-10-6020-5_12

Cdk5 phosphorylates Cdh1 and modulates cyclin B1 stability in excitotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-981-10-6020-5_12

Nuclear localization of Cdk5 is a key determinant in the postmitotic state of neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-981-10-6020-5_12

A Jekyll and Hyde kinase: roles for Cdk5 in brain development and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-981-10-6020-5_12

Neuronal cyclin-dependent kinase 5: role in nervous system function and its specific inhibition by the Cdk5 inhibitory peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-981-10-6020-5_12

Secrets of a double agent: CDK7 in cell-cycle control and transcription

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-981-10-6020-5_12

CAK-Cyclin-dependent Activating Kinase: a key kinase in cell cycle control and a target for drugs?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-981-10-6020-5_12

E2F1 represses beta-catenin transcription and is antagonized by both pRB and CDK8

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-981-10-6020-5_12

Cellular control of gene expression by T-type cyclin/CDK9 complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-981-10-6020-5_12

Cdk10, a Cdc2-related kinase, associates with the Ets2 transcription factor and modulates its transactivation activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-981-10-6020-5_12

Role of CDK/cyclin complexes in transcription and RNA splicing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-981-10-6020-5_12

Cdk11 is a RanGTP-dependent microtubule stabilization factor that regulates spindle assembly rate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-981-10-6020-5_12

CDK11(p58) is required for the maintenance of sister chromatid cohesion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-981-10-6020-5_12

14-3-3sigma controls mitotic translation to facilitate cytokinesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-981-10-6020-5_12

The PITSLRE/CDK11p58 protein kinase promotes centrosome maturation and bipolar spindle formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-981-10-6020-5_12

The history and future of targeting cyclin-dependent kinases in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-981-10-6020-5_12

A novel cyclin encoded by a bcl1-linked candidate oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-981-10-6020-5_12

Cyclin D1 and mammary carcinoma: new insights from transgenic mouse models

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-981-10-6020-5_12

Estrogens and cell-cycle regulation in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-981-10-6020-5_12

Cyclin D as a therapeutic target in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-981-10-6020-5_12

Signaling through cyclin D-dependent kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-981-10-6020-5_12

The functional loss of the retinoblastoma tumour suppressor is a common event in basal-like and luminal B breast carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-981-10-6020-5_12

Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-981-10-6020-5_12

Cyclin D1 induction in breast cancer cells shortens G1 and is sufficient for cells arrested in G1 to complete the cell cycle

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-981-10-6020-5_12

Specific protection against breast cancers by cyclin D1 ablation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-981-10-6020-5_12

The role of the cyclin D1-dependent kinases in ErbB2-mediated breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-981-10-6020-5_12

Cyclin D1 and breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-981-10-6020-5_12

Cyclin D1 stimulation of estrogen receptor transcriptional activity independent of cdk4

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-981-10-6020-5_12

CDK-independent activation of estrogen receptor by cyclin D1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-981-10-6020-5_12

Repeated observation of breast tumor subtypes in independent gene expression data sets

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-981-10-6020-5_12

Cyclin E overexpression, a negative prognostic factor in breast cancer with strong correlation to oestrogen receptor status

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-981-10-6020-5_12

Cyclin-E is a strong predictor of endocrine therapy failure in human breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-981-10-6020-5_12

Cyclin E and survival in patients with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-981-10-6020-5_12

Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-981-10-6020-5_12

Deregulation of cyclin E meets dysfunction in p53: closing the escape hatch on breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-981-10-6020-5_12

Cyclin E amplification, over-expression, and relapse-free survival in HER-2-positive primary breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-981-10-6020-5_12

Prognostic value of cyclin E expression in breast cancer: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-981-10-6020-5_12

Cytoplasmic Cyclin E Predicts Recurrence in Patients with Breast Cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-981-10-6020-5_12

Effects of ErbB-2 overexpression on mitogenic signalling and cell cycle progression in human breast luminal epithelial cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-981-10-6020-5_12

A novel interaction between HER2/neu and cyclin E in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-981-10-6020-5_12

Tumor-specific low molecular weight forms of cyclin E induce genomic instability and resistance to p21, p27, and antiestrogens in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-981-10-6020-5_12

Cdk2 is required for breast cancer mediated by the low-molecular-weight isoform of cyclin E

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-981-10-6020-5_12

Hypomethylation and increased gene expression of p16INK4a in primary and metastatic breast carcinoma as compared to normal breast tissue.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-981-10-6020-5_12

Lost in transcription: p21 repression, mechanisms, and consequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-981-10-6020-5_12

Optical imaging of metabolism in HER2 overexpressing breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-981-10-6020-5_12

Role of the CDK inhibitor p27 (Kip1) in mammary development and carcinogenesis: insights from knockout mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-981-10-6020-5_12

Cell cycle kinases as therapeutic targets for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-981-10-6020-5_12

Cyclin-dependent kinase inhibitor therapy for hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-981-10-6020-5_12

Flavopiridol, fludarabine, and rituximab in mantle cell lymphoma and indolent B-cell lymphoproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-981-10-6020-5_12

A dose-finding, pharmacokinetic and pharmacodynamic study of a novel schedule of flavopiridol in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-981-10-6020-5_12

Phase I evaluation of seliciclib (R-roscovitine), a novel oral cyclin-dependent kinase inhibitor, in patients with advanced malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-981-10-6020-5_12

Roscovitine confers tumor suppressive effect on therapy-resistant breast tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-981-10-6020-5_12

Seliciclib (CYC202, R-roscovitine) enhances the antitumor effect of doxorubicin in vivo in a breast cancer xenograft model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-981-10-6020-5_12

The small-molecule CDK inhibitor, SNS-032, enhances cellular radiosensitivity in quiescent and hypoxic non-small cell lung cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-981-10-6020-5_12

Phase I and pharmacologic study of SNS-032, a potent and selective Cdk2, 7, and 9 inhibitor, in patients with advanced chronic lymphocytic leukemia and multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-981-10-6020-5_12

A phase 1 study of SNS-032 (formerly BMS-387032), a potent inhibitor of cyclin-dependent kinases 2, 7 and 9 administered as a single oral dose and weekly infusion in patients with metastatic refractory solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-981-10-6020-5_12

Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-981-10-6020-5_12

Dinaciclib is a novel cyclin-dependent kinase inhibitor with significant clinical activity in relapsed and refractory chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-981-10-6020-5_12

A first-in-human, phase 1, dose-escalation study of dinaciclib, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-981-10-6020-5_12

A phase 1 study with dose expansion of the CDK inhibitor dinaciclib (SCH 727965) in combination with epirubicin in patients with metastatic triple negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-981-10-6020-5_12

Randomized phase II trial of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus capecitabine in patients with advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-981-10-6020-5_12

Treating cancer with selective CDK4/6 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-981-10-6020-5_12

Proliferative suppression by CDK4/6 inhibition: complex function of the retinoblastoma pathway in liver tissue and hepatoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-981-10-6020-5_12

Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-981-10-6020-5_12

Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-981-10-6020-5_12

CDK 4/6 inhibitor palbociclib (PD0332991) in Rb+ advanced breast cancer: phase II activity, safety, and predictive biomarker assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-981-10-6020-5_12

The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-981-10-6020-5_12

Palbociclib and Letrozole in Advanced Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-981-10-6020-5_12

The Role of CDK4/6 Inhibition in Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-981-10-6020-5_12

PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-981-10-6020-5_12

CDK4/6 inhibition provides a potent adjunct to Her2-targeted therapies in preclinical breast cancer models

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-981-10-6020-5_12

Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-981-10-6020-5_12

A Phase I Study of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) in Patients with Advanced Solid Tumors and Lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-981-10-6020-5_12

CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-981-10-6020-5_12

Ribociclib plus letrozole in early breast cancer: A presurgical, window-of-opportunity study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-981-10-6020-5_12

Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-981-10-6020-5_12

Semi-mechanistic pharmacokinetic/pharmacodynamic modeling of the antitumor activity of LY2835219, a new cyclin-dependent kinase 4/6 inhibitor, in mice bearing human tumor xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-981-10-6020-5_12

Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-981-10-6020-5_12

Brain Exposure of Two Selective Dual CDK4 and CDK6 Inhibitors and the Antitumor Activity of CDK4 and CDK6 Inhibition in Combination with Temozolomide in an Intracranial Glioblastoma Xenograft

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-981-10-6020-5_12

Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-981-10-6020-5_12

10.1007/978-981-10-6020-5_12

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29282688%20AND%20SRC:MED&resulttype=core&format=json

8 April 2020

1 reference